First-pass extracted concept

multiplex genome editing

Candidate: concept label2 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

Innovations such as multiplex genome editing, immune-evasive donor platforms, synthetic biology, and AI-driven treatment modeling are poised to expand therapeutic horizons.

Evidence 1Source 1DOI PubMedprovenance

the possibility to simultaneously edit multiple genes (multiplex genome editing) in the same cells

Evidence 2Source 2DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Source 2primary paper2025MEDDOI PubMed

1 evidence snippet 2 linked claims Claim 1 Claim 2

Linked Claims

Claim 1future directionsupports2025Source 1DOI PubMed

Multiplex genome editing, immune-evasive donor platforms, synthetic biology, and AI-driven treatment modeling are poised to expand therapeutic horizons.

Quoted textsource-backed

Innovations such as multiplex genome editing, immune-evasive donor platforms, synthetic biology, and AI-driven treatment modeling are poised to expand therapeutic horizons.

Claim 2manufacturing optimizationsupports2025Source 2DOI PubMed

T-cell manufacturing protocols optimized for persistence and resistance to immune suppression are facilitated by multiplex genome editing in the same cells.

Quoted textsource-backed

Integration of T-cell manufacturing protocols optimized for persistence and resistance to immune suppression-largely facilitated by the possibility to simultaneously edit multiple genes (multiplex genome editing) in the same cells

Claim 3therapeutic positioningsupports2025Source 2DOI PubMed

Engineered T cells have been positioned as programmable and persistent therapeutics.

Quoted textsource-backed

has positioned engineered T cells as programmable and persistent therapeutics